Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Novartis AG Common Stock (NY: NVS )

97.11 +0.34 (+0.35%)
Official Closing Price Updated: 7:00 PM EST, Dec 20, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1,547,663
Open 96.16
Bid (Size) 95.00 (1)
Ask (Size) 100.69 (1)
Prev. Close 96.77
Today's Range 96.06 - 97.59
52wk Range 92.35 - 120.92
Shares Outstanding N/A
Dividend Yield 3.89%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Your Healthcare Costs are Soaring! US Spending Reached $5 Trillion In 2023 with Major Increase in Obesity and Diabetes Drugs, Hospital Services
U.S. healthcare spending grew 7.5% to $4.9 trillion in 2023, with hospital care and prescription drugs driving costs. Private insurance accounted for 30% of total spending. 
Via Benzinga
For those who appreciate value investing, NYSE:NVS is a compelling option with its solid fundamentals.
NOVARTIS AG-SPONSORED ADR (NYSE:NVS) is a prime example of a stock that offers more than what meets the eye in terms of fundamentals. 
Via Chartmill

Performance

YTD
-3.85%
-3.85%
1 Month
-6.49%
-6.49%
3 Month
-16.55%
-16.55%
6 Month
-9.20%
-9.20%
1 Year
-1.66%
-1.66%

More News

Read More
Promising Data for Treating Gastrointestinal Cancer Leading to Hopeful Advancements for Pancreatic & Anal Cancers
Via FinancialNewsMedia
Why the dividend investor may take a look at NYSE:NVS.
Via Chartmill
2 Dividend Stocks to Buy and Hold Forever
Via The Motley Fool
Promising Data for Treating Gastrointestinal Cancer Leading to Hopeful Advancements for Pancreatic & Anal Cancers
From FN Media Group LLC
Via GlobeNewswire
Drug Price Hikes Unsupported By Evidence Cost US $815 Million: ICER Report
Via Benzinga
Exploring NYSE:NVS's dividend characteristics.
Via Chartmill
Is NYSE:NVS suited for dividend investing?
Via Chartmill
Novartis Reports Q3 Momentum, But Shares Lose Support
Via Investor's Business Daily
UniQure Stock Nearly Doubles After Striking A Deal With The FDA For Huntington's Drug
Via Investor's Business Daily
Exposures Product Safety
Novartis Touts Encouraging Data From Late-Stage Study For Fabhalta In Rare Type Of Blood Disorder
Via Benzinga
Janux Therapeutics' Prostate Cancer Trial Data Exceeds Investor Expectations: Analyst
Via Benzinga
PTC Therapeutics Inks Licensing Pact With Novartis Worth Up To ~$3 Billion For Huntington's Program
Via Benzinga
PTC Therapeutics Scores A $2.9 Billion Novartis Deal And Hits Profit-Taking Zone
Via Investor's Business Daily
Novartis Elevates Midterm Sales Forecast, CEO Highlights Robust Pipeline
Via Benzinga
Schrödinger Scores Big Despite Q3 Miss As Novartis Collaboration Promises Billions In Milestones: Details
Via Benzinga
Stock Market Retreats Before Election Day; Microsoft, Apple, Amazon, Google, Meta In Focus: Weekly Review
Via Investor's Business Daily
Positive Outlook For Novartis As Company Capitalizes On Growing Treatment Opportunities, Analyst Highlights
Via Benzinga
Lyell Immunopharma Downgraded, Analyst Flags Concerns Over Acquisition Strategy
Via Benzinga
Novartis Ag (NVS) Q3 2024 Earnings Call Transcript
Via The Motley Fool
Topics Earnings
Exposures Financial
Novartis Q3 Earnings Beats Expectations On Strong Sales From Key Drugs, Lifts 2024 Outlook
Via Benzinga
Topics Earnings
Exposures Financial
Monte Rosa Stock Doubles — Up 127% — On A Massive Deal With Novartis
Via Investor's Business Daily
“Top Biotech Opportunities: RVNC, HCTI, GLUE, PRSO, CRDL, Showing Promising Developments”
Via AB Newswire
Topics Artificial Intelligence
Exposures Artificial Intelligence
Why Is Monte Rosa Therapeutics Stock Surging On Monday?
Via Benzinga
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.